The identification of luteinizing hormone-releasing hormone (LHRH) amino acid structure in the early 1970s [7,9] and the development of some of its analogs, long-acting delivery formulations, and antagonists for the treatment of prostate cancer was reported by the group of Dr. Schally and others [7]. The gene discussed is GNRH1; the disease is Familial prostate cancer.